Aminoglycosides: Definition, Contraindications, and Side Effects
What Are Aminoglycosides?
Aminoglycosides are a class of rapidly bactericidal antibiotics derived from actinomycetes, used primarily to treat serious gram-negative bacterial infections, including multidrug-resistant pathogens. 1, 2, 3
Common aminoglycosides include:
- Gentamicin (most commonly used in UK neonatal units)
- Amikacin
- Tobramycin
- Streptomycin
- Neomycin
These antibiotics work through concentration-dependent killing, meaning higher peak concentrations relative to the pathogen's minimum inhibitory concentration (MIC) correlate with better clinical outcomes 4. They are particularly valuable against resistant gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumannii, and extended-spectrum β-lactamase-producing Enterobacterales 2.
Absolute Contraindications
The following conditions absolutely contraindicate aminoglycoside use: 5
- Hypersensitivity to aminoglycosides or other drugs in this class
- Myasthenia gravis - aminoglycosides impair neuromuscular transmission and can precipitate respiratory failure
- Pregnancy (second and third trimester) - risk of permanent vestibular or auditory nerve damage to the fetus
Major Side Effects
Nephrotoxicity (Kidney Damage)
Aminoglycosides cause dose-dependent, usually reversible kidney damage through accumulation in proximal tubule cells. 5, 1
- Occurs through buildup of phospholipids in lysosomes, inhibiting their function
- Risk increases with prolonged use, higher cumulative doses, and concurrent nephrotoxic drugs
- Monitor renal function twice weekly during month 1, weekly during month 2, then fortnightly 5
- Fortunately, changes in renal function are typically reversible once the drug is stopped
Ototoxicity (Hearing and Balance Damage)
Aminoglycosides cause permanent, irreversible damage to hearing and balance organs. 5, 1
Auditory toxicity:
- Hearing loss usually occurs first
- Caused by reactive oxygen species damaging mitochondria in hair cells, resulting in cell death
- Risk factors: older age, prolonged use, cumulative dose
- Streptomycin is least associated with hearing loss among the aminoglycosides 5
- Permanent and irreversible once it occurs
Vestibular toxicity:
- Presents as vertigo, loss of balance, tinnitus
- Usually resolves but can be permanent
- Found in approximately 9% of patients in prospective studies 5
Critical monitoring requirement: Perform baseline audiometry, then monthly during treatment. Define ototoxicity as 20 dB loss at any one frequency OR 10 dB loss at two adjacent frequencies - if this occurs, discontinue aminoglycoside immediately 5.
Neuromuscular Blockade
- Can impair neuromuscular transmission
- Particularly dangerous in myasthenia gravis patients
High-Risk Situations Requiring Extreme Caution
Avoid aminoglycosides in patients with cirrhosis and ascites - they are associated with high incidence of nephrotoxicity and should be reserved only for severe bacterial infections that cannot be treated with other antibiotics 6.
Severe renal dysfunction - once-daily dosing should not be used in patients with severe renal impairment where the aminoglycoside is not expected to clear within several days 4, 7.
Concurrent nephrotoxic drugs increase risk:
- Loop diuretics (increased ototoxicity risk)
- Capreomycin
- Cephalosporins
- Ciclosporin
- Colistimethate sodium
- Tacrolimus
- Bisphosphonates (increased hypocalcemia risk) 5
Critical Dosing Considerations to Minimize Toxicity
Once-daily dosing (5-7 mg/kg gentamicin equivalent) yields comparable efficacy with possibly decreased renal toxicity compared to multiple daily dosing 4, 7. This approach:
- Optimizes peak concentrations for bacterial killing
- Allows adequate drug-free intervals to minimize toxicity
- Requires therapeutic drug monitoring to ensure trough concentrations remain sufficiently low (target trough <5 mg/L for amikacin) 5
Treatment with aminoglycosides alone is suboptimal - they should be used in combination therapy for serious infections 8.
Common Pitfall to Avoid
The most critical error is continuing aminoglycoside therapy after ototoxicity develops. Hearing loss that has occurred is permanent and irreversible - the drug must be stopped immediately upon detection of audiometric changes 5. Do not wait for symptomatic hearing loss; rely on regular audiometric testing.